Next Article in Journal
Essential Thrombocythemia and Acquired von Willebrand Syndrome: The Shadowlands between Thrombosis and Bleeding
Next Article in Special Issue
Midline Meningiomas of the Anterior Skull Base: Surgical Outcomes and a Decision-Making Algorithm for Classic Skull Base Approaches
Previous Article in Journal
Y Chromosome Loss Is a Frequent Event in Barrett’s Adenocarcinoma and Associated with Poor Outcome
Previous Article in Special Issue
Boron Neutron Capture Therapy and Photodynamic Therapy for High-Grade Meningiomas

The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma

Peninsula Schools of Medicine and Dentistry, Institute of Translational and Stratified Medicine, Plymouth University, Plymouth PL68BU, UK
Takeda International UK, 1 Kingdom Street, London W2 6BD, UK
Millennium Pharmaceuticals, Inc. a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA 02139, USA
Department of Histopathology, University Hospitals Plymouth NHS Trust, Plymouth, Devon PL6 8DH, UK
Author to whom correspondence should be addressed.
Cancers 2020, 12(7), 1744;
Received: 6 May 2020 / Revised: 16 June 2020 / Accepted: 29 June 2020 / Published: 30 June 2020
(This article belongs to the Special Issue Meningioma: Genomic Discoveries and Recent Therapeutic Advances)
Meningioma is the most common primary intracranial tumour, and surgical resection is the main therapeutic option. Merlin is a tumour suppressor protein that is frequently mutated in meningioma. The activity of the E3 ubiquitin ligase complex, CRL4-DCAF1, and the Raf/MEK/ERK scaffold protein Kinase suppressor of Ras 1 (KSR1) are upregulated in Merlin-deficient tumours, which drives tumour growth. Identifying small molecules that inhibit these key pathways may provide an effective treatment option for patients with meningioma. We used meningioma tissue and primary cells derived from meningioma tumours to investigate the expression of DDB1 and Cullin 4-associated factor 1 (DCAF1) and KSR1, and confirmed these proteins were overexpressed. We then used primary cells to assess the therapeutic potential of MLN3651, a neddylation inhibitor which impacts the activity of the CRL family of E3 ubiquitin ligases and the MAPK/ERK kinase (MEK1/2) inhibitor selumetinib. MLN3651 treatment reduced proliferation and activated apoptosis, whilst increasing Raf/MEK/ERK pathway activation. The combination of MLN3651 and the MEK1/2 inhibitor selumetinib prevented the increase in Raf/MEK/ERK activity, and had an additive effect compared with either treatment alone. Therefore, the combined targeting of CRL4-DCAF1 and Raf/MEK/ERK activity represents an attractive novel strategy in the treatment of Merlin-deficient meningioma. View Full-Text
Keywords: Merlin; meningioma; CRL4-DCAF1; KSR1; Raf/MEK/ERK Merlin; meningioma; CRL4-DCAF1; KSR1; Raf/MEK/ERK
Show Figures

Graphical abstract

MDPI and ACS Style

Lyons Rimmer, J.; Ercolano, E.; Baiz, D.; Makhija, M.; Berger, A.; Sells, T.; Stroud, S.; Hilton, D.; Adams, C.L.; Hanemann, C.O. The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma. Cancers 2020, 12, 1744.

AMA Style

Lyons Rimmer J, Ercolano E, Baiz D, Makhija M, Berger A, Sells T, Stroud S, Hilton D, Adams CL, Hanemann CO. The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma. Cancers. 2020; 12(7):1744.

Chicago/Turabian Style

Lyons Rimmer, Jade, Emanuela Ercolano, Daniele Baiz, Mahindra Makhija, Allison Berger, Todd Sells, Steve Stroud, David Hilton, Claire L. Adams, and C O. Hanemann 2020. "The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma" Cancers 12, no. 7: 1744.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop